Postpartum depression statistics: the maternal mental health crisis in numbers

She was three weeks postpartum when she stopped sleeping. Not because the baby was keeping her up. Her mother-in-law was handling the night feedings, but her mind would not turn off. She sat in the dark thinking she had made a terrible mistake becoming a mother. At her six-week checkup, she told me she was "fine, just tired." I asked her to fill out a PHQ-9. She scored 19 out of 27. Severe depression.

Postpartum depression is one of the most common complications of childbirth. It affects roughly 1 in 7 new mothers in the United States, and in some populations the rate is closer to 1 in 5. It is not the "baby blues," which resolve within two weeks. Postpartum depression can persist for months or longer, interfering with bonding, daily function, and in the worst cases, survival. And despite how common it is, about half of all cases are never diagnosed.

This article covers what the most recent data tells us about postpartum depression: how many women it affects, how many are missed, who dies, what it costs, and what has changed with the approval of the first oral treatment in 2023.

How common is postpartum depression

Postpartum depression affects approximately 1 in 7 women after childbirth in the United States. The CDC estimates the prevalence at roughly 13% to 14% of new mothers, though some researchers place the range between 10% and 20% depending on the population studied and the screening tools used.

With about 3.6 million live births in the U.S. each year, that translates to roughly 470,000 to 720,000 women developing postpartum depression annually. That is more women each year than are diagnosed with breast cancer.

A 2005 systematic review by Gavin et al. in Obstetrics & Gynecology, still one of the most frequently cited analyses, estimated the point prevalence at 12.9% during the first three months postpartum. Since then, newer data has consistently pushed the number higher, particularly in populations that include adolescent mothers, women with unplanned pregnancies, and women experiencing socioeconomic hardship.

Postpartum depression is not always limited to the weeks immediately after delivery. Some women develop symptoms months later. The DSM-5 defines the "peripartum" specifier as onset during pregnancy or within four weeks of delivery, but clinicians increasingly recognize that symptoms frequently emerge up to a year postpartum. The ACOG screening guidelines from 2018 acknowledge this broader window.

The diagnosis gap

Here is the number that should concern anyone working in maternal care: about half of women with postpartum depression are never diagnosed.

A 2013 study by Wisner et al. published in JAMA Psychiatry screened 10,000 postpartum women and found that among those who screened positive for depression, a significant proportion had never been identified by their healthcare providers. The barriers were multiple. Some women did not disclose their symptoms. Some were not asked. Some were screened but their positive results were not followed up on.

Part of the problem is structural. In the United States, the standard postpartum care model includes a single visit at six weeks after delivery. Six weeks. A woman goes through one of the most physically and psychologically demanding events of her life, and the healthcare system checks in once before closing the chart. ACOG has recommended shifting to ongoing postpartum care, but implementation has been slow.

There is also the issue of shame. Many women expect motherhood to feel joyful and interpret depressive symptoms as personal failure. I have had patients tell me they felt too guilty to admit they were not happy. That silence is a diagnostic barrier no screening tool can overcome on its own.

If you are pregnant or recently postpartum and tracking your cycle patterns, our period calculator can help you understand when your cycle might return, but pay attention to your mood alongside your physical recovery. The two are connected.

Maternal suicide and mortality

Maternal suicide is a leading cause of death among women in the first year after giving birth.

Data from CDC Maternal Mortality Review Committees, covering 36 U.S. states from 2017 to 2019, found that mental health conditions were associated with approximately 23% of pregnancy-related deaths. That includes suicide and overdose deaths linked to untreated or inadequately treated psychiatric illness. Among those deaths, the majority occurred between 43 days and one year postpartum. That is outside the traditional six-week window where most postpartum monitoring ends.

This timing matters. It means the healthcare system is functionally blind during the period when women are most likely to die from mental health causes.

The data on suicide specifically is grim. A 2024 analysis by the National Institutes of Health found that suicide during the perinatal period is significantly underreported because many death certificates do not record pregnancy status. When researchers linked death records to birth records directly, the maternal suicide rate was substantially higher than previously estimated.

These are not inevitable deaths. They are deaths that happen in a gap: between the end of obstetric care and the beginning of nothing. Women leave the hospital with a baby and a follow-up appointment six weeks away, and some of them do not make it to that appointment.

The economic burden

A 2020 study published in the American Journal of Public Health by Luca et al. calculated the societal costs of untreated perinatal mood and anxiety disorders among the 2017 U.S. birth cohort. The total came to $14.2 billion.

That figure includes direct medical costs for the mother, productivity losses, and the long-term costs associated with adverse child outcomes. Because untreated maternal depression is linked to developmental delays, behavioral problems, and impaired attachment in children, the costs ripple forward for years.

Broken down, the study estimated approximately $32,000 in costs per affected mother-infant pair over a five-year period. For context, the cost of screening and treating postpartum depression (including an Edinburgh Postnatal Depression Scale screening, clinical evaluation, and a course of therapy or medication) typically runs $2,000 to $4,000. The return on investment for treatment is not subtle.

Category	Estimated cost
Untreated cost per mother-infant pair (5 years)	$32,000
Zuranolone (14-day course, wholesale)	$15,900
Screening + therapy or SSRI	$2,000-$4,000

Source: Luca et al., American Journal of Public Health, 2020 (untreated costs); article cost context for zuranolone and screening/treatment.

Yet Medicaid, which covers roughly 42% of all births in the United States, historically terminated coverage at 60 days postpartum in many states. The American Rescue Plan Act of 2021 gave states the option to extend Medicaid postpartum coverage to 12 months, and by early 2025, most states had adopted the extension. That change alone has the potential to reshape diagnosis and treatment access for low-income women.

Who is most at risk

Postpartum depression does not distribute evenly. Certain groups face substantially higher rates.

Women with a prior history of depression or anxiety are 30% to 50% more likely to develop postpartum depression. A history of postpartum depression in a previous pregnancy puts the recurrence risk at roughly 25% to 50%, depending on the study.

Socioeconomic status plays a significant role. Women living below the federal poverty line have rates of postpartum depression roughly twice as high as women with higher incomes. A CDC Pregnancy Risk Assessment Monitoring System (PRAMS) analysis found that self-reported postpartum depression ranged from 9.7% among women with the highest household income to 23.4% among those with the lowest.

Household income	Self-reported postpartum depression
Highest household income	9.7%
Lowest household income	23.4%

Source: CDC Pregnancy Risk Assessment Monitoring System (PRAMS) analysis, as cited in this article.

Racial disparities are present but complicated by the intersection of race with income, insurance status, and access to care. Some data suggests that Black and Hispanic women report higher rates of postpartum depressive symptoms, but they are less likely to receive treatment. A 2019 study in Psychiatric Services found that among women who screened positive for postpartum depression, white women were significantly more likely than women of color to receive a follow-up mental health referral.

Adolescent mothers, women who experience pregnancy complications, women who deliver preterm, and women who lack social support are all at elevated risk. So are women with hormonal conditions that affect mood regulation.

One risk factor that receives insufficient attention is birth trauma. Women who have traumatic birth experiences (emergency cesarean sections, hemorrhage, or perceived loss of control during delivery) develop PTSD at rates between 3% and 6%. PTSD and postpartum depression frequently co-occur, and treating one without addressing the other leads to poor outcomes.

Treatment options and zuranolone

Treatment for postpartum depression has historically relied on the same tools used for major depressive disorder in general: SSRIs, therapy, or both. Sertraline and paroxetine are the most commonly prescribed medications, partly because of their relatively lower transfer into breast milk. Cognitive behavioral therapy (CBT) and interpersonal therapy (IPT) have strong evidence for efficacy in the postpartum period.

The problem is speed. SSRIs typically take 4 to 6 weeks to reach full effect. For a woman in crisis who cannot care for herself or her newborn, a month and a half is a very long time.

In March 2019, the FDA approved brexanolone (Zulresso), the first medication specifically indicated for postpartum depression. Brexanolone is an intravenous infusion of a synthetic form of allopregnanolone, a neurosteroid that drops sharply after delivery. It works within hours. In clinical trials, women showed significant improvement by 24 hours and sustained response at 30 days. The catch: it requires a 60-hour supervised infusion in a certified healthcare facility, at a cost of approximately $34,000 per treatment, not including hospitalization. Uptake has been extremely limited.

That changed, at least in principle, in August 2023, when the FDA approved zuranolone (Zurzuvae), the first oral treatment for postpartum depression. Zuranolone is a neuroactive steroid that works on GABA-A receptors, the same mechanism as brexanolone but in a pill form taken once daily for 14 days.

In the phase 3 SKYLARK trial, women taking zuranolone showed statistically significant improvement in depressive symptoms compared to placebo at day 15, with effects sustained through the 45-day follow-up period. The median time to response was 3 days. That speed is meaningful when you consider the clinical context: a new mother with severe depression who cannot bond with her baby, who may be having intrusive thoughts about self-harm.

There are caveats. Zuranolone carries a boxed warning about central nervous system depression. Patients cannot drive or operate machinery for 12 hours after taking it. The initial wholesale acquisition cost was approximately $15,900 for a 14-day course. Insurance coverage has been inconsistent, and some payers initially classified it as non-formulary. Whether zuranolone reaches the women who most need it, disproportionately low-income women on Medicaid, remains an open question as of early 2026.

Screening gaps in clinical practice

In 2018, ACOG issued Committee Opinion No. 757 recommending that clinicians screen all women for depression and anxiety at least once during the perinatal period using a validated tool such as the Edinburgh Postnatal Depression Scale (EPDS) or the PHQ-9. The U.S. Preventive Services Task Force similarly recommends screening all adults for depression, including pregnant and postpartum women.

Despite these guidelines, screening is far from universal. A 2023 analysis found that fewer than 50% of postpartum women in the United States were screened for depression during the postpartum period, though rates have improved significantly since the early 2010s.

The barriers are predictable. Time constraints in clinical visits. Lack of referral pathways when screens are positive. Insufficient mental health providers, particularly in rural areas. In some states, there are fewer than 5 psychiatrists per 100,000 residents who accept Medicaid.

Pediatric visits offer an underused screening opportunity. Because women see their baby's pediatrician far more frequently than they see their own doctor in the first year postpartum, several states have begun piloting maternal depression screening during well-child visits. Illinois and New Jersey were among the first to mandate it. The results have been promising: screening rates for postpartum depression increased substantially in pediatric settings where protocols were implemented.

If you are planning a pregnancy or are currently pregnant, learning about ovulation and fertility patterns can help you prepare, but preparing for the postpartum period is equally important. Ask your OB about their screening protocol now, before delivery. Know what resources exist in your community. Have a plan.

Frequently asked questions about postpartum depression

How common is postpartum depression?

Approximately 1 in 7 women (13% to 14%) develop postpartum depression after childbirth, according to the CDC. With roughly 3.6 million U.S. births per year, that means 470,000 to 720,000 women are affected annually. Rates are higher among women with low income, prior depression, or inadequate social support, where prevalence can reach 1 in 5.

Is postpartum depression a leading cause of maternal death?

Yes. Mental health conditions, including suicide and overdose, contribute to approximately 23% of pregnancy-related deaths in the United States, according to CDC Maternal Mortality Review Committee data from 2017 to 2019. Maternal suicide is a leading cause of death in the first year after delivery, with most deaths occurring after the six-week postpartum check-up.

What is zuranolone (Zurzuvae)?

Zuranolone is the first oral medication approved by the FDA specifically for postpartum depression. Approved in August 2023, it is a neuroactive steroid taken once daily for 14 days. In clinical trials, women showed improvement in as few as 3 days. The wholesale cost is approximately $15,900 for a full course. It carries a boxed warning about drowsiness and impaired driving.

How much does untreated postpartum depression cost?

A 2020 study in the American Journal of Public Health estimated the societal cost of untreated perinatal mood and anxiety disorders at $14.2 billion for the 2017 U.S. birth cohort. That comes to approximately $32,000 per affected mother-infant pair over five years, including direct medical costs, lost productivity, and adverse outcomes in children.

What percentage of postpartum depression cases go undiagnosed?

Roughly 50% of women with postpartum depression are never diagnosed. Barriers include limited screening at clinical visits, a care model that provides only one postpartum check-up at six weeks, stigma around maternal mental health, and a shortage of mental health providers who accept Medicaid. ACOG recommends screening all women at least once during the perinatal period.

Who is most at risk for postpartum depression?

Women with the highest risk include those with a prior history of depression (30% to 50% higher risk), previous postpartum depression (25% to 50% recurrence), low household income (up to 23% prevalence), lack of social support, traumatic birth experiences, and preterm delivery. Adolescent mothers also face elevated risk. Racial disparities exist in both prevalence and access to treatment.